Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is PT Jayamas Medica Industri Tbk EV-to-EBIT?
PT Jayamas Medica Industri TbkISX:OMED 91 EV-to-EBIT is 8.29 as of Sep. 11, 2026, which is 21% below its 10-year median of 10.54. GuruFocus rates ISX:OMED with a GF Score™ of 91/100 and a GF Value™ of Rp240.27 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 475 Medical Devices & Instruments companies, PT Jayamas Medica Industri Tbk ranks better than 79.37% on this metric.
The historical rank and industry rank for PT Jayamas Medica Industri Tbk's EV-to-EBIT or its related term are showing as below:
ISX:OMED'
s EV-to-EBIT Range Over the Past 10 Years
Min: 7 Med: 10.54 Max: 27.65
Current: 8.28
During the past 7 years, the highest EV-to-EBIT of PT Jayamas Medica Industri Tbk was 27.65. The lowest was 7.00. And the median was 10.54.
ISX:OMED's EV-to-EBIT is ranked better than 79.37% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.21
vs ISX:OMED: 8.28
PT Jayamas Medica Industri Tbk (ISX:OMED) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PT Jayamas Medica Industri Tbk's Enterprise Value for the quarter that ended in Jun. 2026 was Rp4,444,100 Mil.
PT Jayamas Medica Industri Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp562,429 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk EV-to-EBIT Related Terms
PT Jayamas Medica Industri Tbk EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, PT Jayamas Medica Industri Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Jayamas Medica Industri Tbk EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Jayamas Medica Industri Tbk's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PT Jayamas Medica Industri Tbk's EV-to-EBIT falls into.
PT Jayamas Medica Industri Tbk's current Enterprise Value is Rp4,660,165 Mil.
PT Jayamas Medica Industri Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp562,429 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk (ISX:OMED) has a EV-to-EBIT of 8.29 as of Sep. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Jayamas Medica Industri Tbk and its competitors. This is 21% below median its historical median of 10.54. Over the past decade, PT Jayamas Medica Industri Tbk's EV-to-EBIT has ranged from 7.00 to 27.65. According to the industry distribution chart, PT Jayamas Medica Industri Tbk ranks #98 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 20.6%.
Is PT Jayamas Medica Industri Tbk's EV-to-EBIT too high?
PT Jayamas Medica Industri Tbk's current EV-to-EBIT of 8.29 is 21% below median its 10-year median of 10.54. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 27.65. The Medical Devices & Instruments industry median EV-to-EBIT is 18.21. PT Jayamas Medica Industri Tbk's value of 8.29 is 54.5% below this industry median. Based on the distribution chart, PT Jayamas Medica Industri Tbk ranks #98 out of 475 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PT Jayamas Medica Industri Tbk ranks #98 out of 475 companies for EV-to-EBIT. This places PT Jayamas Medica Industri Tbk in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.21. PT Jayamas Medica Industri Tbk's value of 8.29 is 54.5% below this benchmark. Historically, PT Jayamas Medica Industri Tbk's own EV-to-EBIT has ranged from 7.00 to 27.65 over the past decade. While the company's 10-year median is 10.54 vs. the industry median of 18.21, PT Jayamas Medica Industri Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.21, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Jayamas Medica Industri Tbk's current EV-to-EBIT of 8.29 is 54.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Jayamas Medica Industri Tbk and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Jayamas Medica Industri Tbk's current EV-to-EBIT is 8.29, which is 21% below median its own 10-year median of 10.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp240.27, compared to a current price of Rp214.00 — trading 10.9% below its estimated fair value. The current EV-to-EBIT is 8.29, which is 21% below median its 10-year median of 10.54 and 54.5% below the Medical Devices & Instruments industry median of 18.21. PT Jayamas Medica Industri Tbk's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current EV-to-EBIT is 8.29 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued.
The current stock price of Rp214.00 is trading 10.9% below its estimated GF Value™ of Rp240.27.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Modestly Undervalued.
Key valuation signals for ISX:OMED:
EV-to-EBIT: 8.29 (21% below median its 10-year median of 10.54)
GF Value™: Rp240.27 vs. price of Rp214.00 (10.9% below fair value)
Industry Position: 54.5% below the Medical Devices & Instruments median (#98 of 475)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
91GF Score
Get the complete analysis for ISX:OMED
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
